RxDoctor Payments DataLook up a doctor →

Nina Balanchivadze, MD

Hematology & Oncology · Norfolk, VANPI 1215225552

Payments from drug & device makers

$877,110in general payments, 2019–2025

Across 48 payments — averaging $18,273 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$598K
  • AstraZeneca$266K
  • Gilead$6K
  • Novartis$3K
  • Stemline Therapeutics Inc.$2K
  • Daiichi Sankyo Inc.$1K
  • plus $397 from 6 others

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$877,110 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$2,476,540
Medicare patients
804
Services billed
126,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →